SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has reported a strong start to 2025 with notable revenue and profit gains in the first quarter, signaling resilience amid global trade complexities and bolstering its long-term value proposition through innovation and strategic acquisitions.
SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has announced a strategic expansion of its radiation oncology solutions, unveiling a suite of AI-driven technologies at the ESTRO 2025 Congress in Vienna, Austria. These developments are designed to streamline oncology workflows, accelerate treatment timelines, and improve clinical outcomes—addressing critical priorities in modern cancer care.
SHERIDAN, WYOMING – May 6, 2025 – GE HealthCare (Nasdaq: GEHC) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Aurora dual-head SPECT/CT system and Clarify DL, a Deep Learning-powered image reconstruction solution. This milestone underscores GE HealthCare’s commitment to advancing nuclear medicine by offering solutions that drive diagnostic precision, streamline workflows, and support evolving clinical needs.
SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers has introduced its Magnetom Flow RT Pro Edition at the European Society for Radiotherapy and Oncology (ESTRO) 2025, marking a significant innovation in magnetic resonance imaging (MRI) tailored for radiation therapy. Designed for operational flexibility and clinical precision, the 1.5 Tesla system addresses longstanding challenges in integrating MRI within radiation oncology environments while offering sustainability and workflow advantages.
SHERIDAN, WYOMING – May 5, 2025 – Siemens Healthineers and Klinikum Region Hannover (KRH) have jointly launched an advanced Infection Control System (ICS) at KRH Klinikum Siloah, a leading regional hospital in Hannover, Germany. The strategic implementation marks a significant move toward reducing hospital-acquired infections (HAIs), improving hygiene standards, and safeguarding both patient and staff well-being across the facility.
Combatting Nosocomial Infections with Innovation
SHERIDAN, WYOMING – May 5, 2025 – Tower Health and Siemens Healthineers have entered a decade-long Value Partnership designed to modernize diagnostic imaging capabilities, enhance operational efficiency, and support long-term clinical excellence across the Tower Health network. The multi-faceted alliance marks a strategic investment in state-of-the-art technology and digital tools aimed at elevating patient care in radiology, oncology, and cardiology services.
Driving Long-Term Value Through Technological Modernization
SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced encouraging 3-month results from its pivotal Omny-IRE clinical trial, spotlighting the high-performance capabilities of its investigational OMNYPULSE™ Platform.
SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has announced the presentation of 22 sponsored or funded clinical studies at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego, showcasing its continued leadership in the electrophysiology space.
SHERIDAN, WYOMING – May 5, 2025 – Johnson & Johnson MedTech has marked a significant milestone in the evolution of robotic-assisted surgery by completing the first clinical trial cases of its OTTAVA™ Robotic Surgical System. This development positions the company at the forefront of innovation in minimally invasive procedures, reinforcing its strategic commitment to delivering cutting-edge surgical technologies that raise standards in operating rooms worldwide.
Strategic Leap in Robotic-Assisted Surgery
SHERIDAN, WYOMING – May 5, 2025 – Shockwave Medical, Inc., a Johnson & Johnson MedTech company and global leader in circulatory restoration, has officially initiated its FORWARD CAD Investigational Device Exemption (IDE) study. This pivotal research effort will evaluate the safety and efficacy of the Shockwave Javelin Coronary IVL Catheter for the treatment of difficult-to-cross, heavily calcified coronary artery lesions—an area with high unmet clinical need and procedural risk.